A Phase 3 interventional study of Insulin Glulisine and Lispro in Diabetes Mellitus, sponsored by Sanofi. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2009-09-15.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing insulin glulisine in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. insulin glulisine · Diabetes Mellitus.
Among the 17 studies testing insulin glulisine in Diabetes Mellitus, this one is the 3rd largest by enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2007, is one of 6 in phase 3, and was the 6th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →None of the 17 studies testing insulin glulisine in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →
insulin glulisine: first FDA approval 2004 (APIDRA SOLOSTAR), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 6 started in 2007.
This study's enrollment of 485 is above the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 169 across the 16 interventional studies. Of the 17 that completed or were terminated, 3 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 17 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
33 studies in Diabetes Mellitus by Sanofi: none open now, none under way, none of them phase 3. Of 33 finished, 0 (0%) have results posted.
Among the 33 studies in Diabetes Mellitus by Sanofi, this one is the 7th largest by enrollment of the 31 interventional ones that give a count, is one of 6 that started in 2007, is one of 12 in phase 3, and was the 13th registered.
Sanofi’s Diabetes Mellitus studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing insulin glulisine in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 33 in Diabetes Mellitus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary:
Secondary:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administration of Insulin Glulisine
Drug: Insulin Glulisine · Drug: Insulin Glargine
Administration of Lispro
Drug: Lispro · Drug: Insulin Glargine
3 times a day before each meal
3 times a day before each meal
once daily
Hypoglycemic episodes
Time frame: From the beginning to end of the study
Change in HbA1c
Time frame: From baseline to endpoint
Adverse events
Time frame: From the beginning to the end of study
Change in HbA1c
Time frame: From baseline to weeks 12
blood glucose parameters, hypoglycemic episodes and dosage of the mealtime and Lantus.
Time frame: from baseline to week 12
The record gives a start of Jan 2007 and a primary completion of Jun 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin glulisine